Images List Premium Download Classic

Psychiatric

Psychiatric-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
Msd R & D (china) Co. Ltd.
May 17, 2018 - N°20180134712

The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (i) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (pde2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, parkinson's disease, parkinson's disease dementia (pdd), or huntington's disease, ...
NEW Ligands selective to alpha 6 subunit-containing gabaa receptors and their methods of use
University Of Belgrade - Faculty Of Pharmacy
May 17, 2018 - N°20180134698

Provided herein are novel pyrazolo-quinolinone compounds and method of using such compounds to treat disorders such as neuropsychiatric disorders with sensorimotor gating deficits, such as schizophrenia, tic disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, panic disorder, huntington's disease and nocturnal enuresis;depression; temporomandibular myofascial pain; disorders of trigeminal nerve, such as trigeminal neuralgia and trigeminal neuropathy; migraine; and tinnitus.
NEW Pupil distortion measurement and psychiatric diagnosis method
May 17, 2018 - N°20180132775

A prediction, diagnosis, or suggesting of a diagnosis of a psychiatric disorder is made based in embodiments of the disclosed technology by determining a shape of one or both pupils in an image of a patient. Such a diagnosis can be made in real-time by diagnosing the patient, or by viewing a digitized version of the patient's face as part ...
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Imidazole derivatives
May 10, 2018 - N°20180125823

The compounds of formula i may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.
Biomarker for psychiatric and neurological disorders
Resvo Inc.
May 03, 2018 - N°20180120328

The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free κ immunoglobulin chains and free λ ...
Substituted imidazopyridine and triazolopyridine analogs as positive allosteric modulators of muscarinic acetylcholine receptor m1
Vanderbilt University
May 03, 2018 - N°20180118746

In one aspect, the invention relates to substituted imidazopyridine and triazolopyridine analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the disclosed ...
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Polymorphic forms of sodium benzoate and uses thereof
Syneurx International (taiwan) Corp.
April 26, 2018 - N°20180111891

The present disclosure provides polymorphic forms of sodium benzoate with a x-ray diffraction pattern comprising characteristic peaks at a reflection angle 2θ of approximately 5. 9, 30. 2, and 31. 2 degrees; or a x-ray diffraction pattern comprising characteristic peaks at a reflection angle 2θ of approximately 3. 7, 5. 9, and 26. 6 degrees. Also provided herein are methods of preparing the polymorphic forms of sodium benzoate and uses ...
Targeted synbiotic therapy for dysbiosis-related intestinal and extra-intestinal disorders
Lifebridge Health, Inc.
April 26, 2018 - N°20180110800

Various types of synbiotic therapies are provided for the treatment of a variety of gastrointestinal and other disorders. The combination of prebiotics to probiotics is defined as a synbiotic therapy. The principal gi disorders associated with dysbiosis that can be treated from such a therapeutic intervention include but are not limited to: inflammatory bowel disease (ibd) (crohn's disease and ulcerative ...
System and method for diagnosis and treatment of neuropsychiatric disorders
Research Foundation For Mental Hygiene, Inc.
April 26, 2018 - N°20180110781

An assay for a gch1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the gch1 gene, alone or in conjunction with a measurement of low or altered ...
Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive ...
Universite Catholique De Louvain
April 26, 2018 - N°20180110742

Disclosed is the use of n-methyl-d-aspartate (nmda) antagonists at sub-anesthetic doses for the treatment of motor dysfunction in mental or psychiatric disorders with occurrence of aggressive and/or impulsive behavior.
Compositions and methods for treating depression
Alexander Vuckovic, M.d., Llc
April 19, 2018 - N°20180104294

Disclosed are a novel combination of specific therapeutics selected from s-adenosyl methionine or a salt thereof, folic acid or a metabolite or salt thereof, and one or more omega-3 fatty acids or salts thereof, useful for a variety of conditions, as discussed herein. Methods of treatment include the treatment of neuropsychiatric conditions, such as depression.
Synergistic combinations of caffeine, ginkgo biloba and beta-phenylethylamine
Trinutra Ltd.
April 19, 2018 - N°20180104292

The present invention provides a therapeutic composition comprising a synergistic combination of caffeine, ginkgo biloba, and β-phenylethylamine (pea) or its salt. The invention is also directed to oral dosage forms containing said composition, and to a method of treatment of a psychological, psychiatric, behavioral and/or neurodevelopmental disorder comprising the administration of said compositions and dosage forms to ...
(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2...
Bristol-myers Squibb Company
April 19, 2018 - N°20180104265

The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nr2b nmda receptor and may be useful for the treatment of various disorders of the central nervous system.
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Potent and selective inhibitors of monoamine transporters; method of making; and use thereof
The United States Of America, As Represented By The Secretary, Department Of Health And Human
April 05, 2018 - N°20180093947

Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (da), serotonin (5-ht), and/or norepinephrine (ne) reuptake via their respective transporters, dat, sert and net. Also disclosed are methods for eliciting a wake-promoting or cognitive or attention enhancing effect and for treating substance use disorders, attention deficit (...
Vigor enhancement via administration of pyrimidine derivatives
University Of Central Florida Research Foundation, Inc.
April 05, 2018 - N°20180092913

Disclosed herein are methods for increasing the overall vigor of a subject, and/or vigor of target tissues of a subject. Exemplified herein is the utilization of pyrimidine derivatives which act to stimulate stem cell proliferation. In addition to increasing vigor, such stem cell proliferation agents (scpa) may be used to enhance and/or improve the outcome of other therapies, ...
Positive allosteric modulators of the muscarinic acetylcholine receptor m4
Vanderbilt University
March 29, 2018 - N°20180086776

Disclosed herein are substituted 8-aminothieno[3,2-e][1,2,4]triazolo[4,3-b]pyridazine-7-carboxamide compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor m4 (machr m4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
Axovant Sciences Gmbh
March 29, 2018 - N°20180085367

The combination of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or a pharmaceutically acceptable salt thereof with a second therapeutic agent, and its use for the treatment of a) psychiatric disorders with prominent cognitive deficits e. G. Chronic ptsd (post traumatic stress disorder); b) non-degenerative disorders with prominent cognitive deficits e. G. Ms (multiple sclerosis), post-chemotherapy, post-cabg (coronary artery bypass graft), post-stroke; and/or ...
Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
Auspex Pharmaceuticals, Inc.
March 29, 2018 - N°20180085327

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar ...
5ht3 receptor antagonists
March 15, 2018 - N°20180072758

That are 5-ht3 receptor antagonists and are therefore useful for the treatment of diseases treatable by inhibition of 5-ht3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and gi disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Selective fkbp51 ligands for treatment of psychiatric disorders
Max-planck-gesellschaft Zur Förderung Der Wissenschaften E.v.
March 15, 2018 - N°20180072667

The present invention relates to compounds having a selective fkbp51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective fkbp51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.
Loading